Aerojet Rocketdyne Holdings Inc. (NYSE: AJRD) was downgraded to Hold from Buy but the price target was raised to $35 from $30 (versus a $34.40 close) at Jefferies. The firm noted that its shares are up 59% since March 31, 2017, (versus a 9% return for the market). Jefferies believes that Aerojet Rocketdyne has a number of long-term growth vehicles, but near-term performance will be offset by lower volumes for space launch programs.

Aimmune Therapeutics Inc. (NASDAQ: AIMT) was reiterated as Outperform and the price target was raised to $70 from $42 (versus a $25.66 close) at Wedbush Securities. This was due to reduced competition for AR101 in peanut allergies.

Cemex SAB de C.V. (NYSE: CX) was raised to Buy from Neutral at Citigroup.

Clovis Oncology Inc. (NASDAQ: CLVS) was started as Overweight with a $105 price target (versus a $77.50 close) at Barclays.

Dr Pepper Snapple Group Inc. (NYSE: DPS) was raised to Outperform from Market Perform with a $98 price target (versus an $89.03 close) at Wells Fargo.

DBV Technologies S.A. (NASDAQ: DBVT) was maintained as Buy but the price target was cut to $37 from $51 (versus a $48.07 close) at Jefferies. The firm noted that Phase 3 data for Viaskin Peanut for peanut allergy is statistically significant, but the effect size is small, missing the lower bound of proposed efficacy range by two points.

Generac Holdings Inc. (NYSE: GNRC) was reiterated as Buy and the price objective was raised to $56 from $50 (versus a $50.59 close) at Merrill Lynch, noting that dealer surveys in Florida alone after Hurricane Irma will keep enough interest in home standby power high through the rest of 2017 and into 2018 for many.

Illumina Inc. (NASDAQ: ILMN) was raised to Neutral from Sell with a $225 fair value estimate (versus a $209.88 close) at Janney. The firm believes that the combination of continuing strength in Microarrays, Services and orders from GRAIL will drive revenue that meets or exceeds expectations.

Nightstar Therapeutics PLC (NASDAQ: NITE) was started as Buy with a $25 price target (versus a $19.00 close) at Jefferies. The firm called Nightstar a pure play gene therapy company that is differentiated through its sole focus on retinal diseases. Wedbush started it as Outperform with a $29 price target, with the firm noting that its lead asset (NSR-REP1) is set to enter Phase 3 with curative potential for choroideremia as a rare inherited retinal disease that has no other approved therapies in the marketplace.

Range Resources Corp. (NYSE: RRC) was downgraded to Neutral from Overweight at JPMorgan.

ServiceNow Inc. (NYSE: NOW) was raised to Overweight from Neutral with a $140 price target (versus a $124.82 close) at Piper Jaffray.

Science Applications International Corp. (NYSE: SAIC) was Raised to Buy From Neutral with an $82 price target (versus a $70.88 close) at Citigroup.

Sierra Oncology Inc. (NASDAQ: SRRA) was raised to Buy from Hold and the price target was raised to $4.00 from $1.50 (versus a $1.64 prior close) at Jefferies. The shares were up 2.5% on Friday and were indicated up another 8% at $1.75 on Monday morning.

SM Energy Co. (NYSE: SM) was raised to Overweight from Neutral with a $30 price target (versus an $18.41 close) at JPMorgan.

With the average analyst Buy or Outperform rating coming about 8% to 10% upside to the price targets at this stage in the bull market, here were 10 very speculative analyst calls for 30% to 200% upside projections from the week of October 20. Just remember those 10 calls were highly speculative and full of much more risk than traditional Dow or S&P 500 companies.

Friday’s top analyst calls included Baidu, Barclays, Celgene, Hewlett Packard Enterprise, Intel, Kimberly-Clark, Lululemon, PayPal, Stratasys and many more.

Get Our Free Investment Newsletter

I have read, and agree to the Terms of Use